Mark X. Sliwkowski - Concepedia

Author

Mark X. Sliwkowski

Also Known As

B. C. Langton, H.-L. Liu, J. Brandis, M SLIWKOWSKI, M Sliwkowski, M X Sliwkowski, M. Sliwkowski, M. X. Sliwkowski, M.X. Sliwkowski, MARK X. SLIWKOWSKI

302

Publications

31.7K

Citations

H-Index

106

Concepts

All Affiliations

Molecular Oncology (United States)National Institutes of Health National Heart Lung and Blood Institute Genentech

About

Mark X. Sliwkowski is an author at Molecular Oncology (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	50	12.9K
2	Natural Sciences	16	16	2.7K
3	Engineering	2	2	81
4	Health Sciences	1	1	29
5	Allergy	1	1	332

Mark X. Sliwkowski

Publications

20.9K

Citations

H-Index

Page 1

	Year	Citations
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger, Cancer Research Drug TargetingBreast OncologyDisulfide LinkersMedicineImmunology	2008	1.6K
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor Jennifer L. Stamos, Mark X. Sliwkowski, Charles Eigenbrot Journal of Biological Chemistry	2002	1.5K
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Jagath R. Junutula, Helga Raab, Suzanna Clark, Nature Biotechnology Medicinal ChemistryImmunocytochemical TechniqueDrug TargetingTherapeutic IndexMedicine	2008	1.3K
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Matthew C. Franklin, Kendall D. Carey, F.F. Vajdos, Cancer Cell Protein FunctionSignal TransductionSignaling PathwayNatural SciencesReceptor Tyrosine Kinase	2004	1.1K
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Ben‐Quan Shen, Keyang Xu, Luna Liu, Nature Biotechnology ImmunoengineeringImmunologyBioconjugationAntibody EngineeringImmunotherapeutics	2012	977
Identification of Heregulin, a Specific Activator of p185 <sup>erbB2</sup> William E. Holmes, Mark X. Sliwkowski, Robert W. Akita, Science	1992	958
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Teemu T. Junttila, Robert W. Akita, Kathryn L. Parsons, Cancer Cell Molecular PharmacologySignaling PathwayMedicineReceptor Tyrosine KinasePharmacotherapy	2009	822
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers Mark D. Pegram, Sheree Hsu, Gail D. Lewis Phillips, Oncogene Inhibitory EffectsOncologyBreast OncologyMedicineImmunology	1999	687
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. Mark X. Sliwkowski, Gabriele Schaefer, Robert W. Akita, Journal of Biological Chemistry Breast OncologyHigh Affinity ReceptorImmunologyMolecular BiologyTumor Biology	1994	643
A Central Role for HER3 in <i>HER2</i> -Amplified Breast Cancer: Implications for Targeted Therapy Si Tuen Lee-Hoeflich, Lisa Crocker, Evelyn Yao, Cancer Research	2008	642

Page 1